Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.

Kyu Ri KangDong Ho HuhJi Ahn KimJin-Han Kang

Published in: BMC immunology (2021)

Our results confirmed the immunogenicity of GC Pharma's Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.

Keyphrases

poor prognosis
immune response
cell therapy
gas chromatography
long non coding rna
mass spectrometry
mesenchymal stem cells
breast reconstruction